Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Corvus Pharmaceuticals Inc CRVS

Healthcare Biotechnology
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in... see more

Recent & Breaking News (NDAQ:CRVS)

Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine Antagonist

GlobeNewswire January 8, 2019

The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede

Benzinga.com  December 27, 2018

The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel

Benzinga.com  December 12, 2018

The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings

Benzinga.com  November 28, 2018

The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

Benzinga.com  November 27, 2018

Report: Exploring Fundamental Drivers Behind Berry Petroleum, Quotient, Virco Manufacturing, Corvus Pharmaceuticals, Marine Products, and Hamilton Beach Brands Holding — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire November 13, 2018

Corvus Pharmaceuticals to Present at the 27th Annual Credit Suisse Healthcare Conference

GlobeNewswire November 12, 2018

Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting

GlobeNewswire November 10, 2018

Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 10, 2018

GlobeNewswire November 5, 2018

Corvus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

GlobeNewswire November 1, 2018

Corvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker Associated with Patient Response to CPI-444 at European Society for Medical Oncology (ESMO) 2018 Congress

GlobeNewswire October 22, 2018

Corvus Pharmaceuticals to Present Data on Lead Programs at the European Society for Medical Oncology (ESMO) 2018 Congress and the Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire October 4, 2018

Corvus Pharmaceuticals Announces Publication of Preclinical Results Highlighting Antitumor Activity of CPI-444 in Multiple Tumor Models both as Monotherapy and in Combination Studies

GlobeNewswire October 3, 2018

Corvus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 25, 2018

Corvus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

GlobeNewswire August 2, 2018

Corvus Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference

GlobeNewswire July 31, 2018

Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, Immunotherapy

GlobeNewswire June 28, 2018

Corvus Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference

GlobeNewswire May 30, 2018

Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

GlobeNewswire May 3, 2018

Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock

GlobeNewswire March 12, 2018